A prospective study of insulin sensitivity and glucose metabolism in women using a continuous subdermal levonorgestrel implant system

Journal of the Society for Gynecologic Investigation

Volumn 4, Issue 2, 1997, Pages 86-89

  Harper, Margaret A ^a,b   Meis, Paul J ^a   Steele, Linda ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b Medical Center Boulevard ^*  (United States)

Author keywords

Glucose metabolism; hormonal contraception; insulin sensitivity; levonorgestrel

Indexed keywords

LEVONORGESTREL;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HORMONAL CONTRACEPTION; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRADERMAL DRUG ADMINISTRATION; INTRAVENOUS GLUCOSE TOLERANCE TEST; LONGITUDINAL STUDY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; BLOOD GLUCOSE; CONTRACEPTIVE AGENTS, FEMALE; DRUG IMPLANTS; FASTING; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; LEVONORGESTREL; LONGITUDINAL STUDIES; PROSPECTIVE STUDIES;

EID: 0030888231     PISSN: 10715576     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1071-5576(97)00002-6     Document Type: Article

References (26)

1. Waine H, Frieden EH, Caplan HZ, et al. Metabolic effects of Enovid on rheumatoid patients. Arthritis Rheum 1963;6:796.
2. Spellacy WN, Buhi WC, Birk SA. The effect of estrogens on carbohydrate metabolism: Glucose, insulin and growth hormone studies on one hundred and seventy-one women ingesting Premarin, mestranol, and ethinyl estradiol for six months. Am J Obstet Gynecol 1972;114:378-92.
3. Kalkoff RK. Effects of oral contraceptive agents on carbohydrate metabolism. J Steroid Biochem 1975;6:949-56.
4. Spellacy WN, Buhi WC, Birk SA. The effects of norgestrel on carbohydrate and lipid metabolism over one year. Am J Obstet Gynecol 1976;125:984-6.
5. Spellacy WN, Buhi WC, Birk SA. Carbohydrate metabolism prospectively studied in women using a low-estrogen oral contraceptive for six months. Contraception 1979;20:137-48.
6. Wynn V, Adams PW, Godsland I, et al. Comparison of effects of different combined oral-contraceptive formulations on carbohydrate and lipid metabolism. Lancet 1979;i:1045-9.
7. Spellacy WN, Buhi WC, Birk SA. Prospective studies of carbohydrate metabolism in "normal" women using norgestrel for eighteen months. Fertil Steril 1981;35:167-71.
8. Spellacy WN. Carbohydrate metabolism during treatment with estrogen, progestogen, and low-dose oral contraceptives. Am J Obstet Gynecol 1982;142:732-4.
9. Spellacy WN, Buhi WC, Birk SA. The effects of two years of mestranol treatment on carbohydrate metabolism. Metabolism 1982;31:1006-8.
10. Briggs MH, Briggs M. Randomized prospective studies on metabolic effects of oral contraceptives. Acta Obstet Gynecol Scand Suppl 1982;105:25-31.
11. Kung AWC, Ma JTC, Wong VCW, et al. Glucose and lipid metabolism with triphasic oral contraceptives in women with history of gestational diabetes. Contraception 1987;35:257-9.
12. Spellacy WN, Ellingson AB, Kotlik A, Tsibris JCM. Plasma glucose and insulin levels in women using a levonorgestrelcontaining triphasic oral contraceptive for three months. Contraception 1988;38:27-35.
13. Godsland IF, Crook D, Simpson R, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990:323:1375-81.
14. Srivastava MC, Oakley NW, Tompkins CV, Sonksen PH, Wynn V. Insulin metabolism, insulin sensitivity and hormonal responses to insulin infusion in patients taking oral contraceptive steroids. Eur J Clin Invest 1975;5:425-33.
15. Kasdorf G, Kalkhoff RK. Prospective studies of insulin sensitivity in normal women receiving oral contraceptive agents. J Clin Endocrinol Metab 1988;66:846-52.
16. Godsland IF, Walton C, Felton C, Proudler S, Patel A, Wynn V. Insulin resistance, secretion, and metabolism in users of oral contraceptives. J Clin Endocrinol Metab 1991;74:64-70.
17. Olsson SE, Odlind V, Johansson EDB, Nordstrom ML. Plasma levels of levonorgestrel and free levonorgestrel index in women using Norplant implants or two covered rods (Norplant-2). Contraception 1987;35:215-28.
18. Shoupe D, Mischell DR. Norplant: Subdermal implant system for long-term contraception. Am J Obstet Gynecol 1989;160:1286-92.
19. Yang YJ, Youn JH, Bergman RN. Modified protocols improve insulin sensitivity estimation using the minimal model. Am J Physiol 1987;253:E595-602.
20. Bergman RN, Phillips LS, Cobelle C. Physiologic evaluation of factors controlling glucose tolerance in man. Measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 1981;68:1456-67.
21. Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. Endocr Rev 1985:6:45-86.
22. Beard JC, Bergman RN, Ward WK, Porte D Jr. The insulin sensitivity index in nondiabetic man. Correlation between clamp-derived and IVGTT-derived values. Diabetes 1986;35:362-9.
23. Pacini G, Bergman RN. Minmod: A computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test. Comput Methods Programs Biomed 1986;23:113-22.
24. Konje JC, Otolorin EO, Ladipo OA. The effect of continuous subdermal levonorgestrel (Norplant) on carbohydrate metabolism. Am J Obstet Gynecol 1992;166:15-9.
25. Bergman RN, Prager R, Volund A, Olefsky JM. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest 1987;79:790-800.
26. Shamma FN, Rosse G, HajHassan L, et al. The effect of Norplant on glucose metabolism under hyperglycemic conditions. Fertil Steril 1995;63:767-72.